Xizang Haisco Pharmaceutical Group Co Ltd (002653) - Total Assets
Based on the latest financial reports, Xizang Haisco Pharmaceutical Group Co Ltd (002653) holds total assets worth CN¥7.66 Billion CNY (≈ $1.12 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Xizang Haisco Pharmaceutical Group Co Lt (002653) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Xizang Haisco Pharmaceutical Group Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data.
Xizang Haisco Pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Xizang Haisco Pharmaceutical Group Co Ltd's total assets of CN¥7.66 Billion consist of 40.4% current assets and 59.6% non-current assets. Also see 002653 market cap overview for the company's overall valuation and market capitalisation.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 19.8% |
| Accounts Receivable | CN¥880.98 Million | 12.6% |
| Inventory | CN¥306.77 Million | 4.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥2.47 Billion | 35.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Xizang Haisco Pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 002653 stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Xizang Haisco Pharmaceutical Group Co Ltd's current assets represent 40.4% of total assets in 2025, a decrease from 71.3% in 2008.
- Cash Position: Cash and equivalents constituted 19.8% of total assets in 2025, down from 21.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 35.0% of total assets, an increase from 3.0% in 2008.
- Asset Diversification: The largest asset category is intangible assets at 35.2% of total assets.
Xizang Haisco Pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of Xizang Haisco Pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
Germany | €22.06 Million |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Xizang Haisco Pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 1.91 | 1.20 |
| Quick Ratio | 1.81 | 1.70 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.64 Billion | CN¥1.36 Billion | CN¥292.58 Million |
Xizang Haisco Pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between Xizang Haisco Pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.93 |
| Latest Market Cap to Assets Ratio | 1.64 |
| Asset Growth Rate (YoY) | 3.1% |
| Total Assets | CN¥7.01 Billion |
| Market Capitalization | $11.52 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Xizang Haisco Pharmaceutical Group Co Ltd's assets above their book value (1.64x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Xizang Haisco Pharmaceutical Group Co Ltd's assets grew by 3.1% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Xizang Haisco Pharmaceutical Group Co Ltd (2008–2025)
The table below shows the annual total assets of Xizang Haisco Pharmaceutical Group Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥7.01 Billion ≈ $1.03 Billion |
+3.12% |
| 2024-12-31 | CN¥6.80 Billion ≈ $994.82 Million |
+2.19% |
| 2023-12-31 | CN¥6.65 Billion ≈ $973.53 Million |
+10.01% |
| 2022-12-31 | CN¥6.05 Billion ≈ $884.95 Million |
+20.82% |
| 2021-12-31 | CN¥5.01 Billion ≈ $732.43 Million |
+0.11% |
| 2020-12-31 | CN¥5.00 Billion ≈ $731.65 Million |
-0.70% |
| 2019-12-31 | CN¥5.04 Billion ≈ $736.82 Million |
+15.33% |
| 2018-12-31 | CN¥4.37 Billion ≈ $638.86 Million |
+6.26% |
| 2017-12-31 | CN¥4.11 Billion ≈ $601.25 Million |
+9.76% |
| 2016-12-31 | CN¥3.74 Billion ≈ $547.80 Million |
+15.99% |
| 2015-12-31 | CN¥3.23 Billion ≈ $472.29 Million |
+12.27% |
| 2014-12-31 | CN¥2.87 Billion ≈ $420.69 Million |
+17.00% |
| 2013-12-31 | CN¥2.46 Billion ≈ $359.56 Million |
+26.25% |
| 2012-12-31 | CN¥1.95 Billion ≈ $284.80 Million |
+120.49% |
| 2011-12-31 | CN¥882.70 Million ≈ $129.17 Million |
+40.14% |
| 2010-12-31 | CN¥629.88 Million ≈ $92.17 Million |
+80.28% |
| 2009-12-31 | CN¥349.39 Million ≈ $51.13 Million |
-1.21% |
| 2008-12-31 | CN¥353.69 Million ≈ $51.76 Million |
-- |
About Xizang Haisco Pharmaceutical Group Co Ltd
Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research c… Read more